Mumbai, Feb. 2 -- Lupin announced a strategic collaboration with TB Alliance, a nonprofit drug developer, to advance the clinical development and commercialization of the investigational drug Telacebec (formerly known as Q203), for the treatment of multiple mycobacterial diseases including tuberculosis (TB), leprosy, and buruli ulcer.

Published by HT Digital Content Services with permission from Capital Market....